RPL7

Large ribosomal subunit protein uL30 · P18124 · RPL7 on Sugi Atlas →

3,677 patent compounds predicted against RPL7, 1,927 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE2	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma	PHASE1	COMPLETED
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors	PHASE1	ACTIVE_NOT_RECRUITING
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients	nan	COMPLETED
Exercise-induced Epigenetic Adaptations	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL7 binder may also engage these)

Protein	Name	Similarity
Q5R9R4	—	1.000	Q5R9R4 →
Q58DT1	—	1.000	Q58DT1 →
Q5ZJ56	—	0.999	Q5ZJ56 →
Q4R506	—	0.998	Q4R506 →
P14148	—	0.995	P14148 →
P05426	—	0.994	P05426 →
G1SV32	—	0.992	G1SV32 →
Q7SBD5	—	0.990	Q7SBD5 →
Q6C603	—	0.990	Q6C603 →
P05737	—	0.988	P05737 →
Q9LHP1	—	0.987	Q9LHP1 →
P32100	—	0.987	P32100 →
P60039	—	0.987	P60039 →
P11874	—	0.986	P11874 →
O01802	—	0.986	O01802 →
P60040	—	0.985	P60040 →
Q5RAH8	—	0.984	Q5RAH8 →
Q12213	—	0.984	Q12213 →
Q6FSN6	—	0.983	Q6FSN6 →
A0CEY2	—	0.983	A0CEY2 →
P17937	—	0.981	P17937 →
O60143	—	0.981	O60143 →
Q6DKI1	—	0.981	Q6DKI1 →
Q9D8M4	—	0.981	Q9D8M4 →
A0BD73	—	0.980	A0BD73 →
A0A1D8PDL6	—	0.980	A0A1D8PDL6 →
A5GFQ0	—	0.980	A5GFQ0 →
Q6BTA4	—	0.980	Q6BTA4 →
Q755A7	—	0.979	Q755A7 →
P25457	—	0.977	P25457 →